Abstract 274P
Background
Index tumors are recognized as the most aggressive prostate tumors; however, their clinical implications remain unclear. This study aimed to investigate the occurrence of index tumor localization based on zonal origin and explore the impact of these locations on the prognosis after radical prostatectomy among patients with negative surgical margins.
Methods
In this retrospective, single-center study, a cohort of 1,109 consecutive patients who underwent radical prostatectomy was analyzed. The index tumor was defined as the largest tumor within the prostate gland. Localization was determined using McNeal's zonal origin classification on whole-mount sections. Kaplan-Meier survival curves were employed to assess biochemical recurrence (BCR)-free survival. Univariate and multivariate Cox proportional hazards analyses were conducted to identify predictive factors for early BCR (within 1 year).
Results
Among the 621 patients with negative surgical margins and no adjuvant therapy, index tumors were localized in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). A total of 22 patients (3.5%) experienced early BCR, and 70 patients (11.2%) experienced overall BCR during a median follow-up period of 61.7 months. Based on index tumor location, the early BCR-free rates were 99.5%, 95.7%, and 83.3% for the transitional, peripheral, and central zones, respectively. Multivariate analysis identified the index tumor in the central zone as an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by the pathological grade of the prostatectomy specimen, index tumor in the peripheral zone, and a high prostate-specific antigen level.
Conclusions
This study examined the significance of index tumor location among patients with negative surgical margins after radical prostatectomy. Notably, index tumors situated in the central zone, although infrequent, emerged as the most robust predictors of early BCR. These findings may prompt urologists and patients to reconsider their therapeutic strategies for prostate cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract